GW Pharmaceuticals Plc Stock News

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmac

GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.

Investors cheered an unexpected acquisition of the cannabinoid-focused biotech.

Jazz Pharmaceuticals said on Wednesday it would buy GW Pharmaceuticals in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding cannabis-based epilepsy treatment. CNBC's Ji

Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share

Medical cannabis stocks and stocks of cannabinoid drug companies are rallying big time Wednesday, the catalyst being a multi-billion-dollar buyout in the space.

Jazz Pharmaceuticals is buying GW Pharma for $7.2 billion in cash and stock, or $220 per share. CNBC's Becky Quick reports.

The stock price of GW Pharmaceuticals PLC (NASDAQ: GWPH) is trading at over 40% pre-market today as of 8:26 AM ET. This is why it happened.

Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per shar

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement

It's a bit of an offbeat company operating in the sector.

Now Is The Time To Build A National Cannabis Brand (Podcast Transcript)

Now Is The Time To Build A National Cannabis Brand (Podcast)

Recently announced provisional Q4 numbers are positive. Company has provided new information in recent conferences on product testing as the pipeline develops.